Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocept, Inc. - Common Stock (NQ: BIOC )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biocept, Inc. - Common Stock

< Previous 1 2 3 Next >
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
From Biocept, Inc.
Via Business Wire
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
From Biocept, Inc.
Via Business Wire
Biocept Inc. (NASDAQ: BIOC) Near the Top of Equities by Percentage Gain on 5/19
Via Investor Brand Network
Biocept to Participate in the H.C. Wainwright Global Investment Conference
From Biocept, Inc.
Via Business Wire
Biocept to Hold Business Update Conference Call on August 30, 2023
From Biocept, Inc.
Via Business Wire
Biocept Reports Second Quarter 2023 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
From Biocept, Inc.
Via Business Wire
Biocept Announces the Passing of Board Chair M. Faye Wilson
From Biocept, Inc.
Via Business Wire
Biocept Names Antonino Morales as President and Chief Executive Officer
From Biocept, Inc.
Via Business Wire
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology
From Biocept, Inc.
Via Business Wire
BioMedNewsBreaks – Biocept Inc. (NASDAQ: BIOC) Releases Pricing on Public Offering
Via Investor Brand Network
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
From Biocept, Inc.
Via Business Wire
Biocept Announces One-for-Thirty Reverse Stock Split
From Biocept, Inc.
Via Business Wire
Biocept Reports First Quarter 2023 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Reports 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
From Biocept, Inc.
Via Business Wire
Biocept Reports Third Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
From Biocept, Inc.
Via Business Wire
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept Reports Second Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept to Present at the LD Micro Main Event XV
From Biocept, Inc.
Via Business Wire
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Appoints RSM as Independent Auditor
From Biocept, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.